Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm Freenome ...

Love & Joy Family Clinic announced an expansion of its screening offerings that strengthens the practice's cancer screenin ...

Author:Shweta Raskar, Business Development Specialist, Prophecy Market InsightsIntroductionThe Multi-Cancer Early Detection (MCED) Market is witnessing an unprecedented surge as diagnostic ...

PanTracer LBx will strengthen NeoGenomics’ pan-solid tumor CGP portfolio and position it in the growing $3 to $5 billion ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with 95% accuracy ...

Q2 2025 Management View Helmy Eltoukhy, Co-CEO, stated that "Q2 marked another exceptional quarter for Guardant. We continue to build momentum across oncology, biopharma and screening business lines, ...

Gnosis, a Southern California-based diagnostic lab advancing women's health through molecular innovation, today announced the national launch of EdenDx, which stands for Early Detection for ...

NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy ...